Kodiak Sciences Inc.

Kodiak Sciences Inc. is a biopharmaceutical company focused on developing novel therapies for retinal diseases, enhancing treatment options for conditions such as age-related macular degeneration and diabetic retinopathy. Founded in 2009, Kodiak Sciences Inc. is dedicated to creating innovative therapeutics for retinal diseases.

Headquartered in Palo Alto, US, the firm has pursued various strategic initiatives to refine its product offerings. The CEO, Victor Perlroth, has a background in biotechnology and has previously been involved in other ventures in the sector. As of October 2018, the company raised USD 90 mn in an IPO, marking a significant milestone in its funding history. The total amount raised by the company amounts to USD 90 mn through 5 deals.

Kodiak Sciences specializes in the design and development of innovative therapeutics for retinal diseases, particularly focusing on high-prevalence conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. The company's flagship product, Tarcocimab Tedromer, is a novel anti-VEGF antibody biopolymer conjugate that is nearing submission for a Biologic License Application following successful pivotal studies. Additionally, KSI-501, a bispecific antibody, is being developed to address retinal inflammation, while KSI-101 targets macular edema. These therapies aim to improve outcomes for patients with complex ocular diseases, primarily in North America and Europe.

Kodiak Sciences generates revenue through the commercialization of its therapeutic products, targeting healthcare providers and institutions involved in ophthalmology. Their transactional model relies on partnerships with hospitals and clinics administering treatments such as Tarcocimab Tedromer and KSI-501. The company also engages in research partnerships and clinical trials to expand its product pipeline. As reported, the EBITDA for the most recent year, 2023, was USD -252.

22 mn. Kodiak Sciences aims to expand its product portfolio with new therapies targeting retinal diseases, leveraging the recent funding from the IPO in October 2018. The company plans to enhance its presence in North American and European markets and is actively exploring opportunities to launch additional products in the coming years. The raised funds of USD 90 mn from the IPO will support these initiatives, facilitating further research and development while enhancing market outreach.